NF-κB Decoy Oligodeoxynucleotide-Coated Balloon Catheter for Arteriovenous Fistula in Hemodialysis

• Published in: Kidney international reports Vol. 4; no. 1; pp. 126 - 138
• Main Authors: Fukasawa, Mizuya, Isobe, Mitsuaki, Nanto, Shinsuke, Nakamura, Masato, Haruguchi, Hiroaki, Miyake, Takashi, Morishita, Ryuichi
• Format: Journal Article
• Language: English
• Published: United States Elsevier 01-01-2019
• Subjects: Clinical Research; hemodialysis; arteriovenous fistula stenosis; percutaneous transluminal angioplasty; nuclear factor κB; balloon catheter; diabetes
• ISSN: 2468-0249; 2468-0249
• DOI: 10.1016/j.ekir.2018.09.016

New treatments to inhibit neointimal formation after percutaneous transluminal angioplasty (PTA) are needed for patients undergoing chronic hemodialysis (HD). We compared the efficacy and safety of AMG0102, a balloon catheter containing nuclear factor κB (NF-κB) decoy oligodeoxynucleotide (ODN) with the PTA balloon catheter (control group) for arteriovenous fistula (AVF) stenosis.
In total, 175 patients (age ≥20 years, undergoing HD, with venous stenosis at the anastomotic region) were registered in this prospective open-label, randomized study. Patients were followed postoperatively for 36 weeks. The duration of primary patency on the targeted venous stenosis site (primary endpoint) was estimated by the Kaplan-Meier method.
A lower restenosis risk was observed for the AMG0102 group, but it was not statistically significant (stratified log-rank test
 = 0.250, hazard ratio [HR] 0.774; 95% confidence interval [CI]: 0.500-1.198). The median duration of primary patency was 245 days and 172 days in the AMG0102 and control groups, respectively. After stratification based on the status of diabetes complications, the HR was 0.666 (95% CI: 0.366-1.212;
 = 0.183) and the median duration of primary patency was prolonged by 108 days in the AMG0102 group with diabetes complications (245 days) compared with the control group (137 days). Adverse event (AE) incidence up to 36 postoperative weeks did not differ between groups. Four device failures occurred in 3 patients (AMG0102 group), but none resulted in AEs.
Further modifications to enhance NF-κB decoy ODN uptake and efficacy are necessary to show its clinical utility for AVF stenosis in chronic HD.